Carter has previously been responsible for increasing retail sales and negotiating new sales opportunities for a number of international pharmacy companies including AAH Pharmaceuticals and Mylan. She has also worked as a prescribing technician for Central Cheshire Primary Care Group.
The company says Carter’s industry credentials and experience of working in both hospital and retail pharmacy will enable the firm to extend its partnerships with hospitals and dispensing doctors.
Quantum appoints national account manager
Pauline Carter brings 18 years’ experience to the role
You may also like
Research & Development
![Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal]()
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal
Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Finance
![Leica Biosystems acquires StatLab to strengthen anatomic pathology and AI-enabled cancer diagnostics]()
Leica Biosystems acquires StatLab to strengthen anatomic pathology and AI-enabled cancer diagnostics
The deal adds StatLab's 50-year histology workflow portfolio to Leica Biosystems' computational pathology platform, supporting laboratory standardisation for AI-driven cancer diagnostics at scale
Manufacturing
![Codis acquires Catalent's Nottingham site to become Europe's leading end-to-end spray dry provider]()
Codis acquires Catalent's Nottingham site to become Europe's leading end-to-end spray dry provider
The deal pairs Nottingham's OSD development and clinical supply expertise with Codis' commercial-scale Haverhill facility, offering pharma partners an integrated ASD development-to-manufacture pathway within a single quality system
Finance
![Novartis to acquire ADC biotech Myricx Bio for $1.5bn]()
Novartis to acquire ADC biotech Myricx Bio for $1.5bn
The pharma giant will add the biotech's novel NMTi payload platform to its roster, which may have potential in multiple solid tumour settings and overcome issues that have troubled ADC therapies, such as payload resistance and tolerability